Stacey Hoisak - Field Trip Sr Counsel
FTHWFDelisted Stock | USD 0.04 0.00 0.00% |
Insider
Stacey Hoisak is Sr Counsel of Field Trip Health
Phone | 833-222-0084 |
Web | https://www.fieldtriphealth.com |
Similar Executives
Showing other executives | INSIDER Age | ||
Dr MBA | Cellectis SA | 46 | |
Daniel Wadsworth | Arch Therapeutics | 69 | |
AGIA ACG | Telix Pharmaceuticals Limited | N/A | |
Christine MBA | SAB Biotherapeutics | 69 | |
M Mukunda | India Globalization Capital | N/A | |
Meredith Crowe | Telix Pharmaceuticals Limited | N/A | |
BEng DPhil | Telix Pharmaceuticals Limited | 47 | |
Mihail MD | MAIA Biotechnology | 65 | |
Lena MoranAdams | Telix Pharmaceuticals Limited | N/A | |
Kyahn Williamson | Telix Pharmaceuticals Limited | N/A | |
MSc MSc | Cellectis SA | 54 | |
Joseph McGuire | MAIA Biotechnology | 66 | |
BSc BSc | Telix Pharmaceuticals Limited | N/A | |
Sujal Patel | Nautilus Biotechnology | 50 | |
Amanda Griffin | Telix Pharmaceuticals Limited | N/A | |
Pascalyne Wilson | Cellectis SA | N/A | |
Daniel Yrigoyen | Arch Therapeutics | 53 | |
Edward DVM | SAB Biotherapeutics | N/A | |
Julie ACA | GH Research PLC | 38 | |
Andreas MD | Telix Pharmaceuticals Limited | N/A | |
Florian M | GH Research PLC | 56 |
Field Trip Health Leadership Team
Elected by the shareholders, the Field Trip's board of directors comprises two types of representatives: Field Trip inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Field. The board's role is to monitor Field Trip's management team and ensure that shareholders' interests are well served. Field Trip's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Field Trip's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ronan Levy, Founder CEO | ||
Chet Lakhani, VP Product | ||
Donna Wong, VP Inc | ||
Vicki Reed, Chief Officer | ||
Mujeeb Jafferi, Founder Pres | ||
Amardeep Manhas, Chief Officer | ||
Stacey Hoisak, Sr Counsel | ||
Edgar Diaz, VP Operations |
Field Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Field Trip a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Current Valuation | 19.22 M | |||
Shares Outstanding | 89.88 M | |||
Shares Owned By Insiders | 22.99 % | |||
Shares Owned By Institutions | 22.41 % | |||
Market Capitalization | 6.96 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Field Pink Sheet
If you are still planning to invest in Field Trip Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Field Trip's history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |